Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Carfilzomib”

228 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 228 results

Testing effectiveness (Phase 2)Study completedNCT03773107
What this trial is testing

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Wake Forest University Health Sciences 12
Testing effectiveness (Phase 2)Ended earlyNCT02294357
What this trial is testing

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Testing effectiveness (Phase 2)Looking for participantsNCT06627751
What this trial is testing

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Who this might be right for
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 28
Not applicableStudy completedNCT02970747
What this trial is testing

Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma in Relapse
iOMEDICO AG 359
Testing effectiveness (Phase 2)Ended earlyNCT03201250
What this trial is testing

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRefractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma
University of Nebraska 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT03556332
What this trial is testing

Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 41
Early research (Phase 1)Study completedNCT02095834
What this trial is testing

Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Ended earlyNCT01658904
What this trial is testing

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

Who this might be right for
Multiple MyelomaLeukemia, Plasma Cell
National Cancer Institute (NCI) 3
Testing effectiveness (Phase 2)UnknownNCT03891355
What this trial is testing

Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Who this might be right for
Mantle Cell Lymphoma
Fondazione Italiana Linfomi - ETS 16
Testing effectiveness (Phase 2)Study completedNCT01470196
What this trial is testing

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute 31
Testing effectiveness (Phase 2)Study completedNCT01941316
What this trial is testing

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Who this might be right for
Small Cell Lung CarcinomaNon Small Cell Lung CarcinomaIrinotecan Sensitive Cancers
Cancer Research and Biostatistics Clinical Trials Consortium 78
Large-scale testing (Phase 3)Looking for participantsNCT06152575
What this trial is testing

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Who this might be right for
Multiple Myeloma
Pfizer 492
Testing effectiveness (Phase 2)UnknownNCT04287855
What this trial is testing

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Poitiers University Hospital 82
Not applicableLooking for participantsNCT06682156
What this trial is testing

Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

Who this might be right for
Newly Diagnosed Multiple Myeloma
The First Affiliated Hospital of Soochow University 50
Not applicableApproved For MarketingNCT01410500
What this trial is testing

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Who this might be right for
Multiple Myeloma
Amgen
Large-scale testing (Phase 3)Active Not RecruitingNCT03729804
What this trial is testing

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

Who this might be right for
Multiple Myeloma
University of Chicago 250
Testing effectiveness (Phase 2)Study completedNCT01989325
What this trial is testing

Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

Who this might be right for
Advanced Multiple Myeloma
Pfizer 77
Large-scale testing (Phase 3)Active Not RecruitingNCT02659293
What this trial is testing

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Chicago 180
Testing effectiveness (Phase 2)Study completedNCT00511238
What this trial is testing

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 312
Early research (Phase 1)Not Yet RecruitingNCT07715903
What this trial is testing

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

Who this might be right for
Colorectal NeoplasmsNeoplasmsIntrahepatic Cholangiocarcinoma+2 more
National Cancer Institute (NCI) 20
Next Page